[VIRTUAL] T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer

[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients.

[VIRTUAL] Preliminary immunogenicity analysis of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with advanced HPV16+ cancers

[VIRTUAL] IVAC-ALL-1: Updated analysis of a phase I/II clinical trial on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia

[VIRTUAL] Ipilimumab, maraviroc and nivolumab in advanced metastatic colorectal and pancreatic cancer. Preliminary results from the phase 1 LUMINESCENCE trial.

[VIRTUAL] Talimogene laherparepvec (T-VEC)-induced tumor oncolysate as a source of tumor antigens and maturation factors for blood-isolated myeloid dendritic cells

[VIRTUAL] Adoptive T cell therapy during chemotherapy with or without Interferon-a in patients with recurrent ovarian cancer.

[VIRTUAL] BNT211: A phase I/IIa trial to evaluate safety and efficacy of CLDN6 CAR-T and CARVac-based in vivo expansion to improve treatment of patients with CLDN6-positive advanced solid tumors.

[VIRTUAL] Monitoring the immune activation in recurrent glioblastoma patients treated with Nivolumab and Bevacizumab

[VIRTUAL] Longitudinal analysis of anti-tumor T-cell responses in vaccinated glioblastoma patients with improved survival

[VIRTUAL] Immune Cell Type Deconvolution by RNA Sequencing Data